DAK HEALTH has floated a tender for Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Omalizumab, Atc R03dx05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months). The project location is Germany and the tender is closing on 05 Jun 2026. The tender notice number is -, while the TOT Ref Number is 102800857. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : Germany

Summary : Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Omalizumab, Atc R03dx05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months)

Deadline : 05 Jun 2026

Other Information

Notice Type : Tender

TOT Ref.No.: 102800857

Document Ref. No. : Login to see details

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : EUR 1.00

Purchaser's Detail

Name : Login to see details

Address : Login to see details

Email : Login to see details

  Login to see details

Documents

 Tender Notice